Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: A nested case-control study in the multiethnic cohort study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Kim, Yeonju ^a   Franke, Adrian A ^a   Shvetsov, Yurii B ^a   Wilkens, Lynne R ^a   Cooney, Robert V ^b   Lurie, Galina ^a   Maskarinec, Gertraud ^a   Hernandez, Brenda Y ^a   Le Marchand, Loïc ^a   Henderson, Brian E ^c   Kolonel, Laurence N ^a   Goodman, Marc T ^a,d  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

25 Hydroxyvitamin D2; 25 Hydroxyvitamin D3; Breast cancer; Ethnic groups; Nested case control study

Indexed keywords

25 HYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; CALCIFEDIOL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; HAWAIIAN; HISPANIC; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RISK REDUCTION; UNITED STATES; VITAMIN BLOOD LEVEL;

EID: 84892473596     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-29     Document Type: Article

References (49)

1. Boscoe FP, Schymura MJ. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer 2006, 6:264. 10.1186/1471-2407-6-264, 1665523, 17096841.
2. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990, 19(4):820-824. 10.1093/ije/19.4.820, 2084008.
3. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94(6):1867-1875. 10.1002/cncr.10427, 11920550.
4. IARC Vitamin D and cancer. IARC Working group reports vol.5 2008, 5. Lyon: International Agency for research on Cancer, IARC.
5. Gissel T, Rejnmark L, Mosekilde L, Vestergaard P. Intake of vitamin D and risk of breast cancer-a meta-analysis. J Steroid Biochem Mol Biol 2008, 111(3-5):195-199.
6. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, Newmark H, Holick MF, Garland FC. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 2007, 103(3-5):708-711.
7. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011, 128(6):1414-1424. 10.1002/ijc.25439, 20473927.
8. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 2010, 46(12):2196-2205. 10.1016/j.ejca.2010.03.037, 20456946.
9. Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J. Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer 2010, 127(9):2159-2168. 10.1002/ijc.25215, 20112341.
10. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Bioiomarkers Prev 2005, 14(8):1991-1997.
11. Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. Breast Cancer Res 2011, 13(3):R50. 10.1186/bcr2880, 3218936, 21569367.
12. Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 2010, 19(9):2341-2350. 10.1158/1055-9965.EPI-10-0264, 20826834.
13. Freedman DM, Chang S-C, Falk RT, Purdue MP, Huang W-Y, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG. Serum levels of Vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2008, 17(4):889-894. 10.1158/1055-9965.EPI-07-2594, 18381472.
14. McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE. Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res 2009, 11(4):R64. 10.1186/bcr2356, 2750126, 19715600.
15. Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, Mosekilde L. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2009, 18(10):2655-2660. 10.1158/1055-9965.EPI-09-0531, 19789365.
16. Scarmo S, Afanasyeva Y, Lenner P, Koenig K, Horst R, Clendenen T, Arslan A, Chen Y, Hallmans G, Lundin E, et al. Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study. Breast Cancer Res 2013, 15(1):R15. 10.1186/bcr3390, 3672761, 23442740.
17. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S, et al. Calcium plus Vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008, 100(22):1581-1591. 10.1093/jnci/djn360, 2673920, 19001601.
18. Neuhouser ML, Manson JE, Millen A, Pettinger M, Margolis K, Jacobs ET, Shikany JM, Vitolins M, Adams-Campbell L, Liu S, et al. The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol 2012, 175(7):673-684. 10.1093/aje/kwr350, 3324430, 22362582.
19. Ford L, Graham V, Wall A, Berg J. Vitamin D concentrations in an UK inner-city multicultural outpatient population. Ann Clin Biochem 2006, 43(Pt 6):468-473.
20. Holick M. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 1995, 61(3):638S-645S.
21. Nessvi S, Johansson L, Jopson J, Stewart A, Reeder A, McKenzie R, Scragg RK. Association of 25-hydroxyvitamin D3)levels in adult New Zealanders with ethnicity, skin color and self-reported skin sensitivity to sun exposure. Photochem Photobiol 2011, 87(5):1173-1178. 10.1111/j.1751-1097.2011.00956.x, 21679191.
22. Ashwell M, Stone EM, Stolte H, Cashman KD, Macdonald H, Lanham-New S, Hiom S, Webb A, Fraser D. UK Food Standards Agency Workshop Report: an investigation of the relative contributions of diet and sunlight to vitamin D status. Br J Nutr 2010, 104(4):603-611. 10.1017/S0007114510002138, 20522274.
23. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008, 88(6):1519-1527. 10.3945/ajcn.2008.26182, 2745830, 19064511.
24. IOM (Institue of Medicine) Dietary reference intakes for calcium and vitamin D 2011, Washington, D.C: The National Academy Press, IOM (Institue of Medicine).
25. Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, et al. IOM Committee Members Respond to Endocrine Society Vitamin D Guideline. J Clin Endocrinol Metab 2012, 97(4):1146-1152. 10.1210/jc.2011-2218, 22442278.
26. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of Vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011, 96(7):1911-1930. 10.1210/jc.2011-0385, 21646368.
27. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine FS. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000, 151(4):346-357. 10.1093/oxfordjournals.aje.a010213, 10695593.
28. Pastor R, Guallar E. Use of two-segmented logistic regression to estimate change-points in epidemiologic studies. Am J Epidemiol 1998, 148(7):631-642. 10.1093/aje/148.7.631, 9778169.
29. Manson JE, Mayne ST, Clinton SK. Vitamin D and prevention of cancer-ready for prime time?. N Engl J Med 2011, 364(15):1385-1387. 10.1056/NEJMp1102022, 21428761.
30. Nicholas J. Vitamin D and cancer: uncertainty persists; research continues. J Natl Cancer Inst 2011, 103(11):851-852. 10.1093/jnci/djr215, 21606436.
31. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008, 87(4):1087S-1091S.
32. Engel P, Fagherazzi G, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Joint effects of dietary vitamin D and sun exposure on breast cancer risk: results from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 2011, 20(1):187-198. 10.1158/1055-9965.EPI-10-1039, 21127286.
33. John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: The NHANES I epidemiologic follow-up study, 1971-1975 to 1992. Cancer Epidemiol Biomarkers Prev 1999, 8(5):399-406.
34. Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr 2011, 94(4):1144-1149. 10.3945/ajcn.111.015032, 3173029, 21880848.
35. Chai W, Maskarinec G, Cooney RV. Serum 25-hydroxyvitamin D levels and mammographic density among premenopausal women in a multiethnic population. Eur J Clin Nutr 2010, 64(6):652-654. 10.1038/ejcn.2010.36, 2900248, 20216557.
36. Kuroda T, Shiraki M, Tanaka S, Ohta H. Contributions of 25-hydroxyvitamin D, co-morbidities and bone mass to mortality in Japanese postmenopausal women. Bone 2009, 44(1):168-172. 10.1016/j.bone.2008.03.023, 19010116.
37. Millen AE, Wactawski-Wende J, Pettinger M, Melamed ML, Tylavsky FA, Liu S, Robbins J, LaCroix AZ, LeBoff MS, Jackson RD. Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr 2010, 91(5):1324-1335. 10.3945/ajcn.2009.28908, 2854906, 20219959.
38. Ohta H, Kuroda T, Onoe Y, Orito S, Ohara M, Kume M, Harada A, Tsugawa N, Okano T, Sasaki S. The impact of lifestyle factors on serum 25-hydroxyvitamin D levels: a cross-sectional study in Japanese women aged 19-25 years. J Bone Miner Metab 2009, 27(6):682-688. 10.1007/s00774-009-0095-1, 19436945.
39. Anderson LN, Cotterchio M, Cole DE, Knight JA. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev 2011, 20(8):1708-1717. 10.1158/1055-9965.EPI-11-0300, 21693626.
40. Ingles SA, Garcia DG, Wang W, Nieters A, Henderson BE, Kolonel LN, Haile RW, Coetzee GA. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control 2000, 11(1):25-30. 10.1023/A:1008979417618, 10680726.
41. McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, Barricarte A, Berg CD, Bergland G, Bingham S, et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 2009, 18(1):297-305. 10.1158/1055-9965.EPI-08-0539, 19124512.
42. Rollison DE, Cole AL, Tung KH, Slattery ML, Baumgartner KB, Byers T, Wolff RK, Giuliano AR. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S. Breast Cancer Res Treat 2011, 132(2):683-691. 3390020, 22130867.
43. Trabert B, Malone KE, Daling JR, Doody DR, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Humphrey MC, Ostrander EA. Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case-control study of Caucasian and African-American women. Breast Cancer Res 2007, 9(6):R84. 10.1186/bcr1833, 2246187, 18067661.
44. Khan QJ, Kimler BF, Fabian CJ. The relationship between vitamin D and breast cancer incidence and natural history. Curr Oncol Rep 2010, 12(2):136-142. 10.1007/s11912-010-0081-8, 20425599.
45. John EM, Schwartz GG, Koo J, Wang W, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol 2007, 166(12):1409-1419. 10.1093/aje/kwm259, 17934201.
46. Li B, Byrjalsen I, Glendenning P, Henriksen DB, Hoeck HC, Taranto M, Vasikaran S, Fraser WD, Christiansen C, Qvist P. Selective monitoring of vitamin D2 and D3 supplementation with a highly specific 25-hydroxyvitamin D3 immunoassay with negligible cross-reactivity to 25-hydroxyvitamin D2. Clin Chim Acta 2009, 404(2):144-148. 10.1016/j.cca.2009.03.043, 19336231.
47. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab 2011, 96(3):E447-452. 10.1210/jc.2010-2230, 21177785.
48. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006, 84(4):694-697.
49. Chlebowski RT. Vitamin D and breast cancer: interpreting current evidence. Breast Cancer Res 2011, 13(4):217. 10.1186/bcr2846, 3236325, 21884640.